Cantor Fitzgerald Analysts Give Teva Pharmaceutical Industries (TEVA) a $18.00 Price Target

Teva Pharmaceutical Industries (NYSE:TEVA) received a $18.00 price objective from research analysts at Cantor Fitzgerald in a research report issued on Thursday. The brokerage currently has a “hold” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential downside of 15.21% from the stock’s current price.

Other analysts have also issued research reports about the stock. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Vetr upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $22.65 price target on the stock in a research report on Wednesday, January 17th. Credit Suisse Group set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, April 4th. Mizuho reiterated a “buy” rating and set a $27.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday, April 20th. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, January 23rd. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $19.82.

Teva Pharmaceutical Industries opened at $21.23 on Thursday, according to MarketBeat Ratings. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 1.80. The company has a market cap of $21.23 billion, a P/E ratio of 5.40, a PEG ratio of 1.71 and a beta of 0.67. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $33.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, May 3rd. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.28. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.80 billion. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The firm’s revenue for the quarter was down 10.0% on a year-over-year basis. During the same quarter last year, the business posted $1.06 EPS. equities analysts expect that Teva Pharmaceutical Industries will post 2.45 EPS for the current year.

In related news, Director Roberto Mignone purchased 750,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, May 10th. The stock was acquired at an average cost of $19.24 per share, for a total transaction of $14,430,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 5,684 shares of company stock valued at $105,411 over the last 90 days. Corporate insiders own 0.43% of the company’s stock.

Large investors have recently bought and sold shares of the business. Calton & Associates Inc. acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth $108,000. Global X Management Co. LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $123,000. Sheaff Brock Investment Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $177,000. Financial Advisory Service Inc. acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $188,000. Finally, ETRADE Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $188,000. Institutional investors and hedge funds own 58.18% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply